Page 70 - Read Online

Diab et al. J Cancer Metastasis Treat 2022;8:42 https://dx.doi.org/10.20517/2394-4722.2022.60 Page 13 of 14

Invest New Drugs 2020;38:800-11. DOI PubMed PMC
54. Beatty GL, Chiorean EG, Fishman MP, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in
mice and humans. Science 2011;331:1612-6. DOI PubMed PMC
55. Beatty GL, Winograd R, Evans RA, et al. Exclusion of T cells from pancreatic carcinomas in mice is regulated by Ly6C(low)
F4/80(+) extratumoral macrophages. Gastroenterology 2015;149:201-10. DOI PubMed PMC
56. Winograd R, Byrne KT, Evans RA, et al. Induction of T-cell immunity overcomes complete resistance to PD-1 and CTLA-4
blockade and improves survival in pancreatic carcinoma. Cancer Immunol Res 2015;3:399-411. DOI PubMed PMC
57. O’hara MH, O’reilly EM, Varadhachary G, et al. CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy,
with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study.
Lancet Oncol 2021;22:118-31. DOI PubMed
58. Lee JW, Stone ML, Porrett PM, et al. Hepatocytes direct the formation of a pro-metastatic niche in the liver. Nature 2019;567:249-
52. DOI PubMed PMC
59. Nielsen SR, Quaranta V, Linford A, et al. Macrophage-secreted granulin supports pancreatic cancer metastasis by inducing liver
fibrosis. Nat Cell Biol 2016;18:549-60. DOI
60. Lohneis P, Sinn M, Bischoff S, et al. Cytotoxic tumour-infiltrating T lymphocytes influence outcome in resected pancreatic ductal
adenocarcinoma. Eur J Cancer 2017;83:290-301. DOI PubMed
61. Steele NG, Carpenter ES, Kemp SB, et al. Multimodal mapping of the tumor and peripheral blood immune landscape in human
pancreatic cancer. Nat Cancer 2020;1:1097-112. DOI PubMed PMC
62. Topcu KSB, Korucu EN, Menevse E, Kocak N, Duran T. Investigation of the effects of the toll-like receptor 4 pathway on immune
checkpoint vista in pancreatic cancer. Invest New Drugs 2022;40:519-28. DOI PubMed
63. Hou Z, Pan Y, Fei Q, et al. Prognostic significance and therapeutic potential of the immune checkpoint VISTA in pancreatic cancer. J
Cancer Res Clin Oncol 2021;147:517-31. DOI PubMed PMC
64. Frey N, Tortola L, Egli D, et al. Loss of Rnf31 and Vps4b sensitizes pancreatic cancer to T cell-mediated killing. Nat Commun
2022;13:1804. DOI PubMed PMC
65. Tian C, Huang Y, Clauser KR, et al. Suppression of pancreatic ductal adenocarcinoma growth and metastasis by fibrillar collagens
produced selectively by tumor cells. Nat Commun 2021;12:2328. DOI PubMed PMC
66. Sahai E, Astsaturov I, Cukierman E, et al. A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev
Cancer 2020;20:174-86. DOI PubMed PMC
67. Akce M, Shaib WL, Diab M, et al. Phase Ib/II trial of siltuximab and spartalizumab in patients in metastatic pancreatic cancer. JCO
2022;40:TPS626-TPS626. DOI
68. Bockorny B, Semenisty V, Macarulla T, et al. BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy
for pancreatic cancer: the COMBAT trial. Nat Med 2020;26:878-85. DOI PubMed
+
69. Seo YD, Jiang X, Sullivan KM, et al. Mobilization of CD8 T cells via CXCR4 blockade facilitates PD-1 checkpoint therapy in
human pancreatic cancer. Clin Cancer Res 2019;25:3934-45. DOI PubMed PMC
70. Feig C, Jones JO, Kraman M, et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-
PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci USA 2013;110:20212-7. DOI PubMed PMC
71. Goulart MR, Stasinos K, Fincham REA, Delvecchio FR, Kocher HM. T cells in pancreatic cancer stroma. World J Gastroenterol
2021;27:7956-68. DOI PubMed PMC
72. Diana A, Wang LM, D’Costa Z, et al. Prognostic value, localization and correlation of PD-1/PD-L1, CD8 and FOXP3 with the
desmoplastic stroma in pancreatic ductal adenocarcinoma. Oncotarget 2016;7:40992-1004. DOI PubMed PMC
73. Tang Y, Xu X, Guo S, et al. An increased abundance of tumor-infiltrating regulatory T cells is correlated with the progression and
prognosis of pancreatic ductal adenocarcinoma. PLoS One 2014;9:e91551. DOI PubMed PMC
74. Zhang Y, Lazarus J, Steele NG, et al. Regulatory T-cell depletion alters the tumor microenvironment and accelerates pancreatic
carcinogenesis. Cancer Discov 2020;10:422-39. DOI PubMed PMC
75. McAllister F, Bailey JM, Alsina J, et al. Oncogenic Kras activates a hematopoietic-to-epithelial IL-17 signaling axis in preinvasive
pancreatic neoplasia. Cancer Cell 2014;25:621-37. DOI PubMed PMC
76. Zhang Y, Zoltan M, Riquelme E, et al. Immune cell production of interleukin 17 Induces stem cell features of pancreatic
intraepithelial neoplasia cells. Gastroenterology 2018;155:210-223.e3. DOI PubMed PMC
+
+
+
neg
77. Barilla RM, Diskin B, Caso RC, et al. Specialized dendritic cells induce tumor-promoting IL-10 IL-17 FoxP3 regulatory CD4 T
cells in pancreatic carcinoma. Nat Commun 2019;10:1424. DOI PubMed PMC
78. Pylayeva-Gupta Y, Das S, Handler JS, et al. IL35-producing B cells promote the development of pancreatic neoplasia. Cancer Discov
2016;6:247-55. DOI PubMed PMC
79. Roghanian A, Fraser C, Kleyman M, Chen J. B Cells promote pancreatic tumorigenesis. Cancer Discov 2016;6:230-2. DOI PubMed
80. Castino GF, Cortese N, Capretti G, et al. Spatial distribution of B cells predicts prognosis in human pancreatic adenocarcinoma.
Oncoimmunology 2016;5:e1085147. DOI PubMed PMC
81. Minici C, Rigamonti E, Lanzillotta M, et al. B lymphocytes contribute to stromal reaction in pancreatic ductal adenocarcinoma.
Oncoimmunology 2020;9:1794359. DOI PubMed PMC
82. Tong DN, Guan J, Sun JH, et al. Characterization of B cell-mediated PD-1/PD-L1 interaction in pancreatic cancer patients. Clin Exp
Pharmacol Physiol 2020;47:1342-9. DOI PubMed